Scientists in San Diego are preparing to screen thousands of people globally to find candidates who are well-suited to take an experimental drug that is designed to slow, and possibly stop, the progression of Alzheimer’s disease.
The study will be led by the University of Southern California’s Alzheimer’s Therapeutic Research Institute—or ATRI—in Sorrento Mesa. Researchers are looking for people who do not have symptoms of Alzheimer’s but do have elevated levels of beta-amyloid.
Amyloid is a protein that can turn into clumpy plaques that damage a person’s ability to think and remember—the hallmarks of Alzheimer’s.
The experimental drug—known as BAN2401—”would attack…
